The depth of mutational agony and the exuberance of tumoral T cell ecstasy predict checkpoint salvation.

Guy, Thomas V; Pillai, Shiv

Guy, Thomas V; Pillai, Shiv.

Afiliación

Guy TV; Illawarra Health and Medical Research Institute, University of Wollongong, Keiraville, Australia. Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Department of Medicine, Harvard University, Cambridge, MA 02139, USA. Email: pillai@helix.mgh.harvard.edu.
Pillai S; Illawarra Health and Medical Research Institute, University of Wollongong, Keiraville, Australia. Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Department of Medicine, Harvard University, Cambridge, MA 02139, USA. Email: pillai@helix.mgh.harvard.edu.

Sci Immunol ; 3(30)2018 12 07.

Article en En | MEDLINE | ID: mdl-30530729

RESUMEN

Genomic biomarkers will help to elucidate which cancer patients will benefit from PD-1 blockade immunotherapy.

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Sci Immunol Año: 2018 Tipo del documento: Article

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google